Boehringer Ingelheim India and PPAM Collaborate to Raise Rabies Awareness in Mumbai Schools

Mumbai, India — Boehringer Ingelheim India, in partnership with the Pet Practitioners Association of Mumbai (PPAM), has taken a significant step toward addressing the critical issue of rabies through a recent educational session at Mumbai Public School, Colaba. This event marks the commencement of the month-long ‘Stop Rabies’ initiative in Mumbai, designed to boost anti-rabies vaccination rates for stray animals, educate the youth about rabies, and emphasize the profound connection between humans and animals in the context of public health.

The ‘Stop Rabies’ initiative, undertaken by Boehringer Ingelheim India and PPAM, is a proactive response to a pressing concern in Mumbai. To date, over 15,000 dogs have been successfully vaccinated, a number set to rise as the campaign gains momentum, with the ultimate goal of ensuring that every uncared-for dog in the city is vaccinated.

Over 100 students participated in the educational session, receiving informative kits consisting of puzzles, stationery, and a booklet filled with valuable insights about rabies.

The event witnessed the presence of key members from Boehringer Ingelheim, including Tawil Mohammed, Regional Managing Director & Head of Human Pharma, Middle East Turkey and Africa (IMETA), Christoph Raab, Head of Finance and Administration, IMETA, Arif Haq, Head of Legal & Compliance, IMETA. The India leadership team was also well-represented, with Gagandeep Singh Bedi, Managing Director and Head of Human Pharma, Dr. Vinod Gopal, Director and Country Head of Animal Health, and Priya Chandramohan, Director of Communication. Dr. Makarand Chavan represented PPAM.

Dr. Kalimpasha A. Pathan, General Manager, Veterinary Health Department and Deonar Abattoir, Brihanmumbai Municipal Corporation, expressed the organization’s dedication to the cause, highlighting the urgency of the initiative in Mumbai’s context.

Tawil Mohammed, Regional Managing Director & Head of Human Pharma, IMETA, stressed that the ‘Stop Rabies’ initiative aligns with Boehringer Ingelheim’s commitment to sustainability, emphasizing the ‘More Health’ pillar as a crucial element of the ‘Sustainable Development – For Generations’ framework. He also noted the enthusiasm and curiosity of the young students in understanding the human-animal bond.

Gagandeep Singh Bedi, Managing Director and Head of Human Pharma at Boehringer Ingelheim India, underscored the societal significance of raising rabies awareness and the collaborative efforts with PPAM and BMC in building a safer, more informed community.

About Boehringer Ingelheim

Boehringer Ingelheim, founded in 1885 and a family-owned company, is dedicated to developing groundbreaking therapies that improve the lives of both humans and animals. As a leading research-driven biopharmaceutical company, they create value through innovation in areas of high unmet medical need. With approximately 53,000 employees serving over 130 markets, Boehringer Ingelheim operates in three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Related posts:

Boehringer Ingelheim Launches Highly Affordable Unbranded Humira Biosimilar Novo Nordisk, Eli Lilly, Boehringer Ingelheim Support Medicare Obesity Drug Coverage Rosie White Joins BMS to Raise Ulcerative Colitis Awareness at The Women’s World Cup Factory Linked to Cough Syrup Deaths in Uzbekistan Gets Permission to Reopen in India